Skip links
OncoOne

Fighting cancer with precision.

Pioneering game-changing radiopharmaceutical therapies.

We Create Targeted Therapies With Curative Potential to Make a Real Difference for Patients

OncoOne develops innovative medicines that target cancer with precision — improving patient outcomes and enhancing quality of life.

About us

PreTarg-it® - Unlocking the Full Potential of Radioimmunotherapy.

At OncoOne, we’re advancing cancer care with our innovative PreTarg-it® platform, which combines targeted antibodies and radiotherapy to treat challenging cancers more precisely

PreTarg-it® - Unlocking the Full Potential of Radioimmunotherapy

At OncoOne, we’re advancing cancer care with our innovative PreTarg-it®  platform, which combines targeted antibodies and radiotherapy to treat challenging cancers more precisely

Oncology

Oncology

Cancer is a leading global cause of death, responsible for nearly one in six fatalities, yet treatment options remain limited. We developed two platform technologies, capitalizing on the discovery of oxMIF and our innovative radiotherapy approach, PreTarg-it®. Our innovative therapies precisely target tumor-associated molecules in a variety of cancers to tackle significant unmet needs in oncology.

Have a tumor target in mind?

Have a tumor target in mind?

Define your target and shape the future of radioimmunotherapy together with us — combining scientific precision, innovative thinking, and strong partnership to to create the therapies of tomorrow.

Your project starts here

Our Cutting Edge Technology

Antibody Design

Our cutting-edge antibody technology drives our ambition to design novel therapeutics.
Learn More >

Anti-oxMIF Platform

The novel antibody pipeline targeting oxMIF unlocks new therapeutic approaches.
Learn More >

PreTarg-it® Platform

The modular platform uses bispecific antibodies for pre-targeted radioimmunotherapy.
Learn More >
NEWSROOM
Investing

Are You Interested in Investing in Future Precision Medicines?

OncoOne is seeking investors for a Series A+ / B financing and is looking for strategic partnerships to propel the development of our diverse and rich pipeline of highly differentiated new precision medicines.

OncoOne would like to explore strategic partnerships that would:

  • Accelerate the clinical development of its pipeline in oncology and chronic inflammation.
  • Leverage the existing expertise of its partner for selected disease areas and drug development.

OncoOne welcomes offers for:

  • Global Licensing Transaction
  • Strategic Alliance
  • Build-to-Buy

OncoOne is open to:

  • Investors for a Series A+/B financing enabling the company to take its first programs into the clinic.
  • Discuss alternative investment approaches, including separate funding of its two platform technologies, Anti-oxMIF antibodies and PreTarg-it®
  • Offers from Corporate Venture Funds for Early Stage strategic investment.
Contact Us

| Public Grants